Driven by a passion for the wellbeing of animals, Regenesis Vet™ makes use of cutting-edge technology and advanced scientific research to produce results-oriented veterinary products.

Based in Cape Town, South Africa, Regenesis Vet™ was founded in 2018 by entrepreneur Alex Miszewski. A competitive showjumper with a love for horses, Alex was in her final year of high school when she cofounded her first successful company selling the world’s first orthotic for sports-horses. Two years later, while completing a Business Science Finance degree, Alex recruited the expertise of renowned expert veterinarians she worked with in the past and Regenesis Vet™ was founded.

Inspired by the injuries her own horse sustained during her show jumping career, Alex set out to build Regenesis Vet™ on the values of accessibility, affordability and hope.

When Alex’s horse suffered her near career-ending injury, she found herself in an unfortunate position she had seen many of her peers experience. From her experience with cutting-edge technology, she had seen how frustrating it could be for those who could not afford the available treatments but so badly needed it. Much of the available technology was not easily accessible, nor was it affordable. Concerned by the fact that there were so few affordable and practical long-term non-invasive regenerative options available, she set out to find a solution.

Her aim in starting Regenesis Vet™ was to help reduce the number of people succeeding her that ended up in a position where the solutions offered to them were inaccessible, unaffordable or impractical for long-term use. Based on these values of accessibility, affordability and hope that there is a different solution, Regenesis Vet™ was born.

With hard work and plenty of determination, Regenesis Vet™ developed the world’s first and only commercially available systemic regenerative equine treatment derived fully from a unique system of processing autologous blood. Subsequent to its development, the system has been worked on and is continuously being improved by leading biomedical scientists.

Regenesis Vet’s™ signature product, Regenesis Vet™ R.I.A.D™ (Recombinant Inflammatory Antagonist Diluent™), was inspired by the remarkable results generated by growth factor therapy- a treatment growing in popularity among injured athletes and those undergoing post-operative care. Growth factor therapy makes use of specific growth factors carefully extracted from the blood to stimulate healing and regeneration of injured or damaged tendons, ligaments and joints.

Thanks to the proprietary activation agent enzyme solution developed by Regenesis Vet™, the above can be achieved without damaging the desired growth factors. Once the process is complete, we are able to extract a concentrated serum which is rich in the targeted growth factors. The finished product promotes faster and better healing, a better immune response and quicker recovery after exercise. This FEI Legal and Jockey Club compliant treatment can be administered immediately or frozen for later use.

The serum offers a strong anti-inflammatory effect and is administered intravenously or injected into the muscle as per your vet’s recommendation. This works to speed up recovery, facilitate the healing process (after surgery or injury) and support tendon and cartilage repair. This ground-breaking treatment not only offers relief and a speedier recovery, but it also has the potential to prolong a horse’s show jumping or racing career, which often is cut short after injury. To find out how Regenesis Vet™ could be beneficial to your horse, speak directly to your vet. A full list of our veterinary partners can be found here.

Regenesis Vet™ is committed to the health and wellbeing of animals and continually strives to find better and more effective treatment solutions.



Regenesis Vet is a division of Novita Biotechnology and is run by the Novita Management team outlined below.


Alexandra Miszewski
Founder & Managing Director

After matriculating from Herschel Girls’ school in 2016, Alexandra Miszewski went on to complete a BBusSci Finance degree at the University of Cape Town (UCT).

She is currently completing a Masters of Finance degree, specialising in Investment Management, at the UCT Graduate School of Business.

Alexandra has always been passionate about problem-solving and entrepreneurship. Her entrepreneurial journey began in 2016 when she co-founded a company by the name of  Equinetendon.com in South Africa. Since then,  Equinetendon.com has grown from a small start-up with a few clients to a multinational company with a global presence.

Read more

Michael Pepper, PhD
Chief Scientific Officer

Michael Pepper is Director of the Institute for Cellular and Molecular Medicine, Director of the South African Medical Research Council Extramural Unit for Stem Cell Research and Therapy, and Research Professor in the Department of Immunology in the Faculty of Health Sciences at the University of Pretoria.

He is also professeur associé in the Department of Genetic Medicine and Development in the Faculty of Medicine at the University of Geneva, Switzerland.

Read more

Mark Bodley , PhD
Chief Regulatory Officer

Dr Mark Bodley is a Business, Quality, Environment, Occupational Health & Safety and Product Safety Management Systems Consultant, Lead Auditor, Trainer and Mentor, in a number of sectors including Medical Devices and Pharmaceuticals. Mark’s experience exceeds 30 years in these fields, ranging from awareness and system training, implementation and auditing. Mark has been the lead Auditor for several ISO Management Systems schemes; mainly ISO 9001, ISO 13485, ISO 22000, ISO 50001, ISO 17025, Chain of Custody (various types) and others.

Read more